<?xml version='1.0' encoding='utf-8'?>
<document id="19141712"><sentence text="Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3."><entity charOffset="13-66" id="DDI-PubMed.19141712.s1.e0" text="lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine]" /></sentence><sentence text="Nucleoside reverse transcriptase inhibitors (NRTIs) need to enter cells to act against the HIV-1" /><sentence text=" Human organic cation transporters (hOCT1-3) are expressed and active in CD4+ T cells, the main target of HIV-1, and have been associated with antiviral uptake in different tissues" /><sentence text=" In this study, we examined whether NRTIs interact and are substrates of hOCT in cells stably expressing these transporters" /><sentence text=" Using [(3)H]N-methyl-4-phenylpyridinium, we found a high-affinity interaction among abacavir [[(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]-cyclopent-2-enyl]methanol sulfate] (ABC); &lt;0"><entity charOffset="7-40" id="DDI-PubMed.19141712.s5.e0" text="[(3)H]N-methyl-4-phenylpyridinium" /><entity charOffset="85-181" id="DDI-PubMed.19141712.s5.e1" text="abacavir [[(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]-cyclopent-2-enyl]methanol sulfate]" /><pair ddi="false" e1="DDI-PubMed.19141712.s5.e0" e2="DDI-PubMed.19141712.s5.e0" /><pair ddi="false" e1="DDI-PubMed.19141712.s5.e0" e2="DDI-PubMed.19141712.s5.e1" /></sentence><sentence text="08 nM], azidothymidine [3'-azido-3'-deoxythymidine (AZT); &lt;0"><entity charOffset="52-55" id="DDI-PubMed.19141712.s6.e0" text="AZT" /></sentence><sentence text="4 nM], tenofovir disoproxil fumarate (&lt;1"><entity charOffset="7-36" id="DDI-PubMed.19141712.s7.e0" text="tenofovir disoproxil fumarate" /></sentence><sentence text="0 nM), and emtricitabine (&lt;2"><entity charOffset="11-24" id="DDI-PubMed.19141712.s8.e0" text="emtricitabine" /></sentence><sentence text="5 nM) and hOCTs" /><sentence text=" Using a wide range of concentrations of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacyitidine (3TC)], we determined two different binding sites for hOCTs: a high-affinity site (K(d1) = 12"><entity charOffset="41-94" id="DDI-PubMed.19141712.s10.e0" text="lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacyitidine" /></sentence><sentence text="3-15" /><sentence text="4 pM) and a low-affinity site (K(d2) = 1" /><sentence text="9-3" /><sentence text="4 mM)" /><sentence text=" Measuring direct uptake of [(3)H]3TC and inhibition with hOCT substrates, we identified 3TC as a novel substrate for hOCT1, 2, and 3, with hOCT1 as the most efficient transporter (K(m) = 1"><entity charOffset="28-37" id="DDI-PubMed.19141712.s15.e0" text="[(3)H]3TC" /><entity charOffset="89-92" id="DDI-PubMed.19141712.s15.e1" text="3TC" /><entity charOffset="34-36" id="DDI-PubMed.19141712.s15.e2" text="3TC" /><pair ddi="false" e1="DDI-PubMed.19141712.s15.e0" e2="DDI-PubMed.19141712.s15.e0" /><pair ddi="false" e1="DDI-PubMed.19141712.s15.e0" e2="DDI-PubMed.19141712.s15.e2" /><pair ddi="false" e1="DDI-PubMed.19141712.s15.e0" e2="DDI-PubMed.19141712.s15.e1" /><pair ddi="false" e1="DDI-PubMed.19141712.s15.e2" e2="DDI-PubMed.19141712.s15.e2" /><pair ddi="false" e1="DDI-PubMed.19141712.s15.e2" e2="DDI-PubMed.19141712.s15.e1" /></sentence><sentence text="25 +/- 0" /><sentence text="1 mM; V(max) = 10" /><sentence text="40 +/- 0" /><sentence text="32 nmol/mg protein/min; V(max)/K(m) = 8" /><sentence text="32 +/- 0" /><sentence text="40 microl/mg protein/min)" /><sentence text=" In drug-drug interaction experiments, we analyzed cis-inhibition of [(3)H]3TC uptake by ABC and AZT and found that 40 to 50% was inhibited at low concentrations of the drugs (K(i) = 22-500 pM)"><entity charOffset="97-99" id="DDI-PubMed.19141712.s22.e0" text="AZT" /><entity charOffset="75-77" id="DDI-PubMed.19141712.s22.e1" text="3TC" /><pair ddi="false" e1="DDI-PubMed.19141712.s22.e1" e2="DDI-PubMed.19141712.s22.e1" /><pair ddi="false" e1="DDI-PubMed.19141712.s22.e1" e2="DDI-PubMed.19141712.s22.e0" /></sentence><sentence text=" These data reveal that NRTIs experience a high-affinity interaction with hOCTs, suggesting a putative role for these drugs as modulators of hOCT activity" /><sentence text=" Finally, 3TC is a novel substrate for hOCTs and the inhibition of its uptake at low concentrations of ABC and AZT could have implications for the pharmacokinetics of 3TC"><entity charOffset="111-113" id="DDI-PubMed.19141712.s24.e0" text="AZT" /><entity charOffset="10-12" id="DDI-PubMed.19141712.s24.e1" text="3TC" /><entity charOffset="167-169" id="DDI-PubMed.19141712.s24.e2" text="3TC" /><pair ddi="false" e1="DDI-PubMed.19141712.s24.e1" e2="DDI-PubMed.19141712.s24.e1" /><pair ddi="false" e1="DDI-PubMed.19141712.s24.e1" e2="DDI-PubMed.19141712.s24.e0" /><pair ddi="false" e1="DDI-PubMed.19141712.s24.e1" e2="DDI-PubMed.19141712.s24.e2" /><pair ddi="false" e1="DDI-PubMed.19141712.s24.e0" e2="DDI-PubMed.19141712.s24.e0" /><pair ddi="false" e1="DDI-PubMed.19141712.s24.e0" e2="DDI-PubMed.19141712.s24.e2" /></sentence><sentence text="" /></document>